Arena Pharmaceuticals, Inc.(NASDAQ: ARNA) stock lost over 5.2% on March 14^th, 2018 (as of  1:43PM EDT; Source: Google finance). For fourth quarter of 2017, the Net loss attributable to stockholders of Arena was $13.7 million, or $0.35 per share.

As per the pipeline update, Phase 3 clinical program preparations for Ralinepag – Oral, next generation, selective prostacyclin receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH) are ongoing. The group forecasts to initiate three studies within the Phase 3 clinical program in H2 2018.

The group’s Etrasimod is Oral, next generation, selective sphingosine-1-phosphate (S1P) receptor modulator intended for the potential treatment of multiple immune and inflammatory diseases. Ulcerative colitis (UC) Phase 2 data is expected by March 2018. Primary biliary cholangitis (PBC) Phase 2 trial is currently enrolling patients. Pyoderma gangrenosum (PG) Phase 2 trial is currently enrolling patients. Phase 2 trial for APD371 – Oral, peripherally restricted, full agonist of the cannabinoid 2 (CB2) receptor intended for the potential treatment of visceral pain, specifically pain associated with Crohn’s disease is currently enrolling patients while the data is forecasted by Q2 2018.

Meanwhile, for the fourth quarter of 2017, the Revenues reached $15.4 million, which comprises $14.2 million in collaboration revenue, and $1.2 million in royalty revenue from Eisai. The group made a development and commercialization partnership with Everest, a C-Bridge Capital-backed biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products in China, for ralinepag and etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea. Over $12.0 million of upfront fee was received from Everest in connection with the development and commercialization partnership.  As per full year of 2017 performance, the Revenues reached $21.3 million, which includes $19.6 million in collaboration revenue, and $1.7 million in royalty revenue from Eisai. The group got over $7.3 million of revenue from the Boehringer Ingelheim and Axovant collaborations during the period.

The group has a cash, cash equivalents and investments balance of $271.3 million as of Dec 2017 and over 39.3 million shares of Arena common stock were outstanding.